Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2005

View Archived Issues

Targeting of HCV IRES to effectively treat chronic hepatitis C virus infection

NS-187: dual Bcr-Abl/Lyn inhibitor

Brivaracetam displays potent anticonvulsant effects in a model of SSSE

Caspase-1 inhibitors attenuate seizures by blocking brain IL-1beta

GlaxoSmithKline completes acquisition of ID Biomedical

AstraZeneca to develop Protherics' CytoFab

Ono and Dainippon Sumitomo sign new agreement for limaprost alfadex

New inhibitor of factor VIIa prevents tissue factor-initiated thrombus formation

Shionogi launches Avelox in Japan

ZymoGenetics profiles R&D programs

Cymbalta to be filed for generalized anxiety disorder in 2006

Canadian clearance for first-in-man study of PPL-100 for drug-resistant HIV

CK-1827452 selected as development candidate for chronic heart failure

Phase III ACUITY study of Angiomax completes enrollment

Treatment begins in phase III study of DX-88 for hereditary angioedema

Prevention and treatment of mammary tumors with a combination of SERM plus rexinoid

PSN-9301 effective in reducing glucose levels

Patient-specific cancer vaccines discussed at hematology meeting

ISA-247 shows long-term safety in patients with moderate to severe psoriasis

NG2-73 shown to promote sleepiness

Novo Nordisk seeks Japanese approval for insulin detemir

Preclinical efficacy of targeting MTAP as an anticancer strategy

Novartis receives U.S. regulatory approval to acquire Chiron

Activation of Nrf2 pathway found to produce antitumorigenic effects in rat liver

Antiamyloidogenic compound also shown to induce neuritogenesis and neuronal differentiation

Recent patents reveal novel agents in early development for schizophrenia, depression, etc.

New treatments for urinary incontinence claimed in recent patents

Novel therapeutic agents for allergic disorders prepared and tested

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...